It may be that enoxacin treatment, by increasing DDRNA expression, could promote 53BP1-mediated repair of DNA lesions, thus preventing senescence and potentially limiting morbidity and even mortality in COVID-19 patients. The gene discussed is TP53BP1; the disease is COVID-19.